Literature DB >> 15507394

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

Jan Storek1, Zhao Zhao, Eugene Lin, Thomas Berger, Peter A McSweeney, Richard A Nash, Yoshiki Akatsuka, Monja D Metcalf, Hailing Lu, Tomas Kalina, Markus Reindl, Rainer Storb, John A Hansen, Keith M Sullivan, George H Kraft, Daniel E Furst, David G Maloney.   

Abstract

To ascertain the consequences of severe leukopenia and the tempo of recovery, we studied the immunity of 56 adult patients treated for multiple sclerosis or systemic sclerosis with autologous CD34 cell transplantation using extremely lymphoablative conditioning. NK cell, monocyte, and neutrophil counts recovered to normal by 1 month; dendritic cell and B cell counts by 6 months; and T cell counts by 2 years posttransplant, although CD4 T cell counts remained borderline low. Initial peripheral expansion was robust for CD8 T cells but only moderate for CD4 T cells. Subsequent thymopoiesis was slow, especially in older patients. Importantly, levels of antibodies, including autoantibodies, did not drop substantially. Infections were frequent during the first 6 months, when all immune cells were deficient, and surprisingly rare (0.21 per patient year) at 7-24 months posttransplant, when only T cells (particularly CD4 T cells) were deficient. In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507394      PMCID: PMC2956741          DOI: 10.1016/j.clim.2004.07.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  49 in total

1.  Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients.

Authors:  V Hammarström; K Pauksen; H Svensson; B Lönnqvist; B Simonsson; O Ringdén; P Ljungman
Journal:  Transplantation       Date:  2000-04-27       Impact factor: 4.939

2.  MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.

Authors:  A Saiz; E Carreras; J Berenguer; J Yagüe; C Martínez; P Marín; M Rovira; T Pujol; T Arbizu; F Graus
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Authors:  M Reindl; C Linington; U Brehm; R Egg; E Dilitz; F Deisenhammer; W Poewe; T Berger
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

4.  Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

Authors:  J Storek; M A Dawson; B Storer; T Stevens-Ayers; D G Maloney; K A Marr; R P Witherspoon; W Bensinger; M E Flowers; P Martin; R Storb; F R Appelbaum; M Boeckh
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 5.  T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.

Authors:  C L Mackall
Journal:  Stem Cells       Date:  2000       Impact factor: 6.277

6.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect.

Authors:  M Mielcarek; W Leisenring; B Torok-Storb; R Storb
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults.

Authors:  C L Mackall; D Stein; T A Fleisher; M R Brown; F T Hakim; C V Bare; S F Leitman; E J Read; C S Carter; L H Wexler; R E Gress
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.

Authors:  H Openshaw; B T Lund; A Kashyap; R Atkinson; I Sniecinski; L P Weiner; S Forman
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

9.  Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.

Authors:  A E Traynor; J Schroeder; R M Rosa; D Cheng; J Stefka; S Mujais; S Baker; R K Burt
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321

10.  Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.

Authors:  D C Douek; R A Vescio; M R Betts; J M Brenchley; B J Hill; L Zhang; J R Berenson; R H Collins; R A Koup
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

View more
  26 in total

1.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.

Authors:  Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

Review 2.  Thymic T-cell development in allogeneic stem cell transplantation.

Authors:  Werner Krenger; Bruce R Blazar; Georg A Holländer
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

3.  Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants.

Authors:  T M Aune; P S Crooke; A E Patrick; J T Tossberg; N J Olsen; C F Spurlock
Journal:  J Autoimmun       Date:  2017-04-15       Impact factor: 7.094

4.  Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Authors:  Keith M Sullivan; Ellen A Goldmuntz; Lynette Keyes-Elstein; Peter A McSweeney; Ashley Pinckney; Beverly Welch; Maureen D Mayes; Richard A Nash; Leslie J Crofford; Barry Eggleston; Sharon Castina; Linda M Griffith; Julia S Goldstein; Dennis Wallace; Oana Craciunescu; Dinesh Khanna; Rodney J Folz; Jonathan Goldin; E William St Clair; James R Seibold; Kristine Phillips; Shin Mineishi; Robert W Simms; Karen Ballen; Mark H Wener; George E Georges; Shelly Heimfeld; Chitra Hosing; Stephen Forman; Suzanne Kafaja; Richard M Silver; Leroy Griffing; Jan Storek; Sharon LeClercq; Richard Brasington; Mary E Csuka; Christopher Bredeson; Carolyn Keever-Taylor; Robyn T Domsic; M Bashar Kahaleh; Thomas Medsger; Daniel E Furst
Journal:  N Engl J Med       Date:  2018-01-04       Impact factor: 91.245

5.  The sialyltransferase ST3Gal-IV guides murine T-cell progenitors to the thymus.

Authors:  Selina Sitte; Daniela Doehler; Markus Sperandio; Jamey D Marth; David Voehringer
Journal:  Blood Adv       Date:  2020-05-12

6.  Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Authors:  Shervin Assassi; Xuan Wang; Guocai Chen; Ellen Goldmuntz; Lynette Keyes-Elstein; Jun Ying; Paul K Wallace; Jacob Turner; W Jim Zheng; Virginia Pascual; John Varga; Monique E Hinchcliff; Chiara Bellocchi; Peter McSweeney; Daniel E Furst; Richard A Nash; Leslie J Crofford; Beverly Welch; Ashley Pinckney; Maureen D Mayes; Keith M Sullivan
Journal:  Ann Rheum Dis       Date:  2019-08-07       Impact factor: 19.103

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

Authors:  Hirohisa Nakamae; Barry E Storer; Rainer Storb; Jan Storek; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; James C Wade; Michael B Maris; Benedetto Bruno; Jens Panse; Effie Petersdorf; Ann Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-10       Impact factor: 5.742

9.  SR-BI (Scavenger Receptor Class B Type 1) Is Critical in Maintaining Normal T-Cell Development and Enhancing Thymic Regeneration.

Authors:  Zhong Zheng; Junting Ai; Ling Guo; Xiang Ye; Subbarao Bondada; Deborah Howatt; Alan Daugherty; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

10.  Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

Authors:  Jan Storek; Zhao Zhao; Yiping Liu; Richard Nash; Peter McSweeney; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.